In the high-stakes world of pharmaceutical research, the quest for reliable "real-world data" (RWD) is often hampered by a fundamental obstacle: the data is as fragmented as the healthcare system itself. On Tuesday, New York-based startup Novellia announced a significant milestone in its mission to resolve this $50 billion industry challenge, securing $18 million in Series A funding. The round, which brings the company’s total lifetime funding to $28 million, underscores a growing investor appetite for platforms that prioritize patient agency in the medical data ecosystem.
The Series A financing was led by Spark Capital, with significant participation from a roster of prominent venture firms, including Khosla Ventures, TMV, Acrew Capital, and Bling Capital. This capital injection is earmarked for scaling Novellia’s patient-permissioned data platform, a technology that seeks to flip the traditional, broker-heavy data model on its head.
A Chronology of Innovation: From Industry Frustration to Patient Empowerment
Founded in 2023, Novellia was born from the direct experience of CEO Shashi Shankar and CTO Elliot Katz. Shankar, a veteran of the pharmaceutical industry, spent nearly a decade at Genentech, where he spearheaded initiatives in real-world data, strategic partnerships, and product launches.
During his tenure at Genentech, Shankar observed a pivotal shift in the regulatory landscape. Emerging interoperability rules, mandated by federal health policy, began to signal a future where patients would finally possess the legal and technical right to access their own comprehensive medical records. However, Shankar noted that while the access was becoming available, the tools to aggregate that data into a cohesive, longitudinal narrative were absent.
The catalyst for the company was personal. After watching his grandfather struggle with gastroesophageal cancer, Shankar saw firsthand the logistical nightmare of care coordination. His mother’s struggle to manage records across disparate health systems, clinics, and laboratories illuminated the vast, systemic failure in how patient data is handled. This professional realization, coupled with a personal mission to simplify the healthcare journey, laid the foundation for Novellia.
The Problem: The "Black Box" of Traditional Data Brokers
For decades, pharmaceutical companies have relied on data brokers—middlemen who aggregate records from health systems, pharmacies, and insurance providers. While these datasets are massive in volume, they are frequently plagued by two critical issues: they are incomplete, and they are devoid of direct patient consent.
"They can’t actually stitch together a single complete patient story," Shankar explained. "If you get on the phone with any pharma company, one of the biggest frustrations is: ‘We’re spending $80-100 million a year on real-world data, and we have no idea what’s going on.’"
Traditional RWD vendors are often limited by the "silo effect." Because a patient might see a primary care physician in one network, a specialist in another, and a lab in a third, the data records rarely communicate. When these records are purchased in bulk from third parties, the resulting datasets often lack the nuance required for high-stakes R&D. Furthermore, the lack of patient-permissioning means researchers are often working with de-identified snippets that lack context, leading to assumptions that may not reflect the actual patient experience.
The Novellia Solution: Patient-Permissioned Data Liquidity
Novellia’s platform operates on a fundamentally different premise: the patient is the most reliable curator of their own health history. The platform allows patients to aggregate their records from virtually any provider, lab, or clinic they have visited, creating a singular, longitudinal view of their health journey.
How the Model Works:
- Patient-Led Aggregation: Users sign up for the platform for free, utilizing modern interoperability standards to pull their fragmented records into one secure, unified digital file.
- Informed Consent: Patients retain control over their data. They can choose to contribute anonymized insights to pharmaceutical research, effectively turning their personal data into a commodity that they voluntarily share.
- Monetization of Insights: Novellia generates revenue by providing these anonymized, high-fidelity datasets to pharmaceutical and diagnostic firms. By bypassing the traditional broker, Novellia claims to provide a cleaner, more complete dataset that reflects the true reality of patient outcomes.
Supporting Data: Validating the Efficacy of Patient-Centered Research
The proof of Novellia’s model lies in its early applications. While many startups in the health-tech space struggle to move beyond pilot programs, Novellia has already established a footprint within the industry’s most prestigious tiers. According to the company, a majority of the top 10 global pharmaceutical companies are already utilizing the platform to refine their R&D efforts.
Case Study: Safety and Efficacy
In a recent engagement, Novellia assisted a client in investigating safety concerns associated with a breast cancer medication. Traditional datasets, which relied on secondary broker reports, had suggested a certain incidence rate of adverse events. By aggregating primary, patient-reported records, Novellia provided a clearer, more accurate picture that actually demonstrated a lower incidence rate than previously feared—a finding that could have massive implications for drug labeling and physician prescribing habits.
Case Study: Care Variation
Novellia has also been instrumental in mapping care variation. By analyzing biomarker testing patterns, the company uncovered significant disparities between physicians practicing at "centers of excellence" versus those in community-based settings. These insights allow pharma companies to better understand where educational initiatives are needed and how different environments impact the efficacy of a treatment.
Data Integrity
Perhaps most compelling is the issue of data validation. In one instance, Novellia was able to identify systematic physician transcription errors in lab records—errors that had gone unnoticed by traditional, automated data processors. By comparing multiple sources against the patient’s own records, Novellia provided a "source of truth" that brokers simply cannot replicate.
Implications for the Future of Healthcare
The rise of Novellia arrives at a time when the pharmaceutical industry is under immense pressure to accelerate drug development while lowering costs. As the cost of "real-world data" continues to skyrocket, the industry is increasingly looking for "high-fidelity" data that provides a higher return on investment.
Shifting the Power Dynamic
By empowering the patient to act as the custodian of their own data, Novellia is effectively democratizing the RWD market. When patients participate in the process—and potentially see the fruits of their participation in the form of better treatments or more accurate safety data—the trust gap between the public and pharmaceutical companies may begin to narrow.
The Regulatory Landscape
The regulatory environment is also shifting in Novellia’s favor. As the Office of the National Coordinator for Health Information Technology (ONC) and other global regulators continue to push for data portability, companies that build their architecture on patient-permissioning are likely to be more resilient to future privacy regulations. Unlike legacy brokers who rely on scraping data, Novellia’s architecture is built for a future where patient consent is the primary gatekeeper.
Looking Ahead: Scaling for Impact
With $28 million in the bank and a client list that includes the heavyweights of the pharmaceutical world, the challenge for Shankar and his team will now be one of scale. Managing the privacy, security, and velocity of high-fidelity health records requires a robust technological infrastructure.
"Healthcare data should work first for patients," Shankar stated during the announcement. "And this will ultimately give way to better insights for researchers too."
As the platform grows, the company plans to expand its partnerships with diagnostics firms and further integrate into the workflows of clinical researchers. If Novellia can prove that patient-provided data is not just more ethical, but significantly more accurate and cost-effective than the current broker-led status quo, they may well define the next decade of pharmaceutical R&D.
In an industry defined by billions of dollars spent on incomplete pictures, Novellia’s bet is simple: if you give patients the keys to their own medical history, they will provide the answers that pharma has been searching for all along.
